Clinical Trial Update: Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 exploratory study evaluating Drug Sensitivity Prediction Software (IRCR-DReSS) using patient-derived tumor cells from metastatic gastric cancer; study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stomach Neoplasms

Drugs mentioned

• IRCR-DReSS

Snippet

Sponsor: Samsung Medical Center | Conditions: Stomach Neoplasms | Phase 2 | Status: COMPLETED